Crude Sickle Cell Birth Prevalence 28.54 per 10,000 in Non-Hispanic Blacks
By Elana Gotkine HealthDay Reporter
MONDAY, April 1, 2024 -- The crude sickle cell disease (SCD) birth prevalence is 28.54 per 10,000 non-Hispanic Black newborns, according to research published in the March 28 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Mariam Kayle, Ph.D., from the Duke University School of Nursing in Durham, North Carolina, and colleagues used state newborn screening program records during 2016 to 2020 from 11 Sickle Cell Data Collection program states to calculate the crude and race-specific birth prevalence for SCD.
Among 3,305 newborns with confirmed SCD across 11 states, the researchers found that the crude SCD birth prevalence was 4.83 per 10,000 livebirths and 28.54 per 10,000 non-Hispanic Black newborns. Among mothers of newborns with SCD, 67 percent lived in counties with high or very high levels of social vulnerability; most mothers lived in counties with high or very high levels of vulnerability for racial and ethnic minority status and with high or very high levels of vulnerability for housing type and transportation themes (89 and 64 percent, respectively).
"These data highlight the potential need to consider tailored interventions in high vulnerability areas to increase access to transportation, improve housing, and advance equity for infants with SCD," the authors write.
Several authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.